Fexofenadine, Ranitidine

Phase 1Small molecule

RRussell Richardson

Fexofenadine, Ranitidine is one of 11 small molecule programs targeting Vascular Function. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vascular FunctionRecruiting

Vascular FunctionPhase 1

Recruiting

Competition

Competitive Landscape

12 competitors in Vascular Function

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Ultram

WWim Janssens

Approved

1 3

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

2 4

Miochol

BBausch Health Americas, Inc.

Phase 1

1 5

L-Citrulline

AAsklepion Pharmaceuticals, LLC

Phase 1

1 6

S-Equol

AAusio Pharmaceuticals, LLC

Phase 2

1 7

Endothelin-1

MMedical University of Vienna

Phase 1

2 8

BQ-123

MMedical University of Vienna

Phase 1

1 9

Fexofenadine, Ranitidine

RRussell Richardson

Phase 1

1 10

BH4

VVA Office of Research and Development

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vascular Function1 trial

: Vascular Function in Health and Disease

Recruiting·RRussell Richardson·Phase 1·NCT02966665·420 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fexofenadine, Ranitidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fexofenadine, Ranitidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fexofenadine, Ranitidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Russell Richardson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRussell Richardson

Fexofenadine, Ranitidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vascular Function1 trial

References

Drug Info

Quick Facts

Related News